Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GXV813 in acute schizophrenia
NCT07467993Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of GXV813 in schizophrenia, sponsored by Novartis. Started Mar 2026; status: recruiting.
02
Drugs
GXV813
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07467993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467993.